Amgen Inc

AMGN

Company Profile

  • Business description

    Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

  • Contact

    One Amgen Center Drive
    Thousand OaksCA91320-1799
    USA

    T: +1 805 447-1000

    E: [email protected]

    https://www.amgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2024

    Employees

    26,700

Amgen Inc News & Analysis

personal-finance

US stock market outlook: tariffs are 2025's wild card

Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks

Obesity drug stocks: Where to invest now

Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
markets

Markets brief: US value stocks have suffered in 2023 but are showing signs of recovery

These stocks have led the latest gains for the value side of the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,471.5018.800.22%
CAC 407,282.6910.370.14%
DAX 4019,848.7735.98-0.18%
Dow JONES (US)43,297.03390.080.91%
FTSE 1008,136.9934.270.42%
HKSE20,098.29215.161.08%
NASDAQ20,031.13266.241.35%
Nikkei 22539,130.4393.580.24%
NZX 50 Index13,074.7486.710.67%
S&P 5006,040.0465.971.10%
S&P/ASX 2008,220.9019.300.24%
SSE Composite Index3,393.5342.271.26%

Market Movers